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The use of CD34+ hematopoietic stem cells (HSC) for transplantation has been limited due to the low CD34+ cell 
numbers in tissue sources such as peripheral blood and cord blood.  Two strategies have been employed to 
increase the CD34+ cell dosage. These include mobilization of HSC into peripheral blood via injection of G-CSF, 
and ex vivo expansion of CD34+ cells. A major limitation of current systems used for the expansion of HSC is 
that ex vivo culture leads to expansion and differentiation of cells, at the expense of the most primitive 
pluripotent long-term HSC. This has limited the clinical application of ex vivo expanded HSC, since short-term 
progenitor cells only provide transient protection, ultimately reducing the positive health outcomes, increasing 
the duration of hospitalizations, and health care costs per patient. Development of a culture system that 
expands, both short term progenitor cells and long-term HSC would enable immune protection during the early 
phase of recovery, and provide a suitable solution for transfusion-independent hematopoiesis. Therefore, we 
have developed an HSC culture medium that enables the expansion of both long-term HSC and short-term 
progenitor cells, while maintaining their functional properties. We conducted several iterative rounds of Design 
of Experiments (DOE) involving multifactorial analysis, and mathematical modeling methods. The DOEs allowed 
us to identify optimal combinations and concentrations of essential media components, small molecules, and 
growth factors. The performance of candidate HSC expansion media were evaluated after 7 days of culture, 
upon which the CD34+ cells and CD34+CD90+CD45RA- cells (long-term HSC) were quantified. We were 
successful in developing a media system- StemPro™ HSC Medium Kit-which is xeno-free, serum-free medium 
that expands both long term CD34+CD90+CD45RA- HSC and short term CD34+. The expression of aldehyde 
dehydrogenase was conducted to identify primitive stem cells, and colony-forming unit assays were performed 
to assess the in vitro differentiation capacity of expanded cells.  We plan to determine whether the expanded 
cells are engraftable by transplanting the cells into immuno-deficient mice. Taken together, we seek to highlight 
our design philosophy in HSC culture media development, and we believe our efforts are critical for the 
successful utilization of hematopoietic stem cell transplants in translational cell therapies.  
 
 
 
 
 
